Učitavanje...
An early look at selective RET inhibitor resistance: new challenges and opportunities
Two RET inhibitors, selpercatinib and pralsetinib, recently received approval for the treatment of advanced RET fusion-positive lung cancer. Acquired resistance to these inhibitors will be a major challenge. We have shown that resistance can emerge due to recurrent RET kinase domain mutations and, i...
Spremljeno u:
| Izdano u: | Br J Cancer |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8144197/ https://ncbi.nlm.nih.gov/pubmed/33758332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01344-7 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|